Optimising ADHD pharmacotherapy across the lifespan

References

1. May T, Murrup-Stewart C, Bellgrove M. Australian evidence-based clinical practice guideline for attention deficit hyperactivity disorder: the role of psychologists. JNZCCP 2023;33(1):18–34.
2. Australasian ADHD Professionals Association. ADHD prescribing guide for Australian healthcare professionals. Melbourne: AADPA. 2024.
3. Cortese S, Bellgrove MA, Coghill D, et al. Attention-deficit/hyperactivity disorder (ADHD) in adults: evidence base, uncertainties and controversies. World Psychiatry 2025;24(3):347–71.
4. Faraone SV. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neurosci Biobehav Rev 2018;87:255–70.
5. Cortese S. Evidence-based prescribing of medications for attention-deficit/hyperactivity disorder: where are we in 2023? Expert Opin Pharmacother 2023;24(4):425–34.
6. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5(9):727–38.
7. Therapeutic Goods Administration. Australian register of therapeutic goods (ARTG). 2025. At: https://www.tga.gov.au/resources/artg
8. Buckley N, ed. Australian medicines handbook. 2025. At: https://amhonline.amh.net.au
9. Cinnamon Bidwell L, Dew RE, Kollins SH. Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder. Curr Psychiatry Rep 2010;12(5):366–73.
10. Arnsten AFT, Jin LE. Guanfacine for the treatment of cognitive disorders: a century of discoveries at Yale. Yale J Biol Med 2012;85(1):45–58.
11. Brikell I, D’Onofrio BM, Lichtenstein P, et